Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Core Insights - Cardiol Therapeutics presented positive results from its Phase II MAvERIC-Pilot study, demonstrating significant reductions in pericarditis pain and inflammation over a 26-week period [1][2][9] - The findings support the advancement of CardiolRx™ into Phase II/III MAVERIC-2 and Phase III MAVERIC-3 clinical trials [1][9] Study Results - The MAvERIC-Pilot study involved 27 participants with an average age of 53 years, showing a mean reduction in pericarditis pain from 5.8 at baseline to 2.1 at week 8, and further to 1.5 at week 26 [2][4][5] - 93% of patients reported a reduction in pain at week 8, and 80% of patients with elevated C-reactive protein (CRP) levels normalized their CRP by week 8 [6][8] - The number of pericarditis episodes per year decreased from an average of 5.8 prior to the study to 0.9 during the study [7] Safety and Tolerability - CardiolRx™ was reported to be safe and well tolerated, with 89% of patients progressing to the extension period and an overall study drug compliance of 95% [8][9] Future Trials - The results from MAvERIC-Pilot support the initiation of the MAVERIC-3 trial, which aims to assess CardiolRx™ for preventing recurrence in pericarditis patients [1][9] - The MAVERIC-2 trial will evaluate the impact of CardiolRx™ in recurrent pericarditis patients after stopping interleukin-1 blocker therapy [1][9]